Summary
Tissue factor (TF) is an initiator of the extrinsic cascade of blood coagulation. Although recent studies have revealed a relationship between metastatic properties and TF expression in some neoplastic cells, the significance of TF in lung cancer, especially in non-small-cell lung cancer (NSCLC), is still unclear. In this study, TF was detected in NSCLC cell lines by functional study, Western blot analysis and immunocytochemical staining. TF levels in eight NSCLC cell lines were also quantitated by enzyme-linked immunosorbent assay (ELISA), and TF expression was evaluated in 55 specimens of surgically resected NSCLCs. NSCLC cell lines derived from metastatic lesions produced high levels of TF (48.3 ± 23.5 ng 10–6 cells, mean ± s.e.m.), whereas those derived from primary lesions produced low levels of TF (0.2 ± 0.1 ng 10–6 cells). Immunohistochemical studies disclosed significantly stronger staining for TF in cells from NSCLC patients with metastasis than in those without metastasis. Among the 28 patients with metastasis, ten were strongly positive, 16 were moderately positive and two were negative for TF. In contrast, among the 27 patients without metastasis, only two were strongly positive, 18 were moderately positive and seven were negative for TF. Therefore, malignant cells from patients with lung cancer produce various levels of TF, and TF may play an important role in the metastatic process.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adamson, A. S., Francis, J. L., Witherow, R. O. & Snell, M. E. (1994a). Procoagulant properties of benign and malignant prostatic tissue. Br J Urol 74: 204–209.
Adamson, A. S., Luckert, P., Pollard, M., Snell, M. E., Amirkhosravi, M. & Francis, J. L. (1994b). Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. Br J Cancer 69: 286–290.
Bromberg, M. E., Konigsberg, W. H., Madison, J. F. & Pawashe, A. (1995). Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 92: 8205–8209.
Callander, N. S., Varki, N. & Rao, L. V. (1992). Immunohistochemical identification of tissue factor in solid tumors. Cancer 70: 1194–1201.
Contrino, J., Hair, G., Kreutzer, D. L. & Rickles, F. R. (1996). In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nature Med 2: 209–215.
Contrino, J., Hair, G. A., Schmeizl, M. A., Rickles, F. R. & Kreutzer, D. L. (1994). In situ characterization of antigenic and functional tissue factor expression in human tumors utilizing monoclonal antibodies and recombinant factor VIIa as probes. Am J Pathol 145: 1315–1322.
Drake, T. A., Morrissey, J. H. & Edgington, T. S. (1989). Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134: 1087–1097.
Esumi, N., Fan, D. & Fidler, I. J. (1991). Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 51: 4549–4556.
Fair, D. S. & MacDonald, M. J. (1987). Cooperative interaction between factor VII and cell surface-expressed tissue factor. J Biol Chem 262: 11692–11698.
Gasic, G. J. (1984). Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metast Rev 3: 99–114.
Gordon, S. G., Franks, J. J. & Lewis, B. (1975). Cancer procoagulant: a factor X-activating procoagulant from malignant tissue. Thromb Res 6: 127–137.
Gunji, Y. & Gorelik, E. (1988). Role of fibrin coagulation in protection of murine tumor cells from destruction by cytotoxic cells. Cancer Res 48: 5216–5221.
Hermanek, P. & Sobin, L. H. (eds) (1992). UICC TNM Classification of Malignant Tumours, 4th edn, 2nd revision. Springer-Verlag: Berlin
Hiraki, S., Miyai, M., Seto, T., Tamura, T., Watanabe, Y., Ozawa, S., Ikeda, H., Nakada, Y., Oonoshi, Y. & Kimura, I. (1982). Establishment of human continuous cell lines from squamous cell, adeno and small cell carcinoma of the lung and the results of heterotransplantation. Haigan 22: 53–57.
Itoh, H., Kataoka, H., Koita, H., Nabeshima, K., Inoue, T., Kangawa, K. & Koono, M. (1991). Establishment of a new human cancer cell line secreting protease nexin-II/amyloid beta protein precursor derived from squamous-cell carcinoma of lung. Int J Cancer 49: 436–443.
Kishimoto, N. (1992). Studies of cell biology and chemotherapy of lung cancer using tissue culture techniques. Part 2. Biological characteristics of five newly establishment small cell lung cancer cell lines. Okayama Igakkai Zasshi 104: 905–913.
Koyama, T., Nishida, K., Ohdama, S., Sawada, M., Murakami, N., Hirosawa, S., Kuriyama, R., Matsuzawa, K., Hasegawa, R. & Aoki, N. (1994). Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 87: 343–347.
Mackman, N. (1995). Regulation of the tissue factor gene. FASEB J 9: 883–889.
Morrissey, J. H., Fair, D. S. & Edgington, T. S. (1988). Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 52: 247–261.
Mountain, C. F. (1993). Lung cancer staging classification. Clin Chest Med 14: 43–53.
Mueller, B. M., Reisfeld, R. A., Edgington, T. S. & Ruf, W. (1992). Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sci USA 89: 11832–11836.
Nemerson, Y. (1988). Tissue factor and hemostasis. Blood 71: 1–8.
Ornstein, D. L., Zacharski, L. R., Memoli, V. A., Kisiel, W., Kudryk, B. J., Hunt, J., Rousseau, S. M. & Stump, D. C. (1991). Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 68: 1061–1067.
Rehemtulla, A., Pepe, M. & Edgington, T. S. (1991). High level expression of recombinant human tissue factor in Chinese hamster ovary cells as a human thromboplastin. Thromb Haemostas 65: 521–527.
Ruf, W. & Edgington, T. S. (1991). An anti-tissue factor monoclonal antibody which inhibits TF. VIIa complex is a potent anticoagulant in plasma. Thromb Haemostas 66: 529–533.
Ruf, W., Rehemtulla, A. & Edgington, T. S. (1991). Antibody mapping of tissue factor implicates two different exon-encoded regions in function. Biochem J 278: 729–733.
Smith, B. T. (1977). Cell line A549: a model system for the study of alveolar type II cell function. Am Rev Respir Dis 115: 285–293.
Wilcox, J. N., Smith, K. M., Schwartz, S. M. & Gordon, D. (1989). Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 86: 2839–2843.
Zhang, Y., Deng, Y., Luther, T., Muller, M., Ziegler, R., Waldherr, R., Stern, D. M. & Nawroth, P. P. (1994). Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94: 1320–1327.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sawada, M., Miyake, S., Ohdama, S. et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 79, 472–477 (1999). https://doi.org/10.1038/sj.bjc.6690073
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690073
Keywords
This article is cited by
-
Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer
Biomarker Research (2023)
-
Integrin regulation by tissue factor promotes cancer stemness and metastatic dissemination in breast cancer
Oncogene (2022)
-
Tissue factor: a neglected role in cancer biology
Journal of Thrombosis and Thrombolysis (2022)
-
Beyond thrombosis: the impact of tissue factor signaling in cancer
Journal of Hematology & Oncology (2020)
-
Antibody–Drug Conjugates in Thoracic Malignancies: Clinical Trials Reveal Both Promise and Challenges
Targeted Oncology (2020)
